The Patent Finder
SB

Sanegene Bio USA Inc.

First filing 2022
OverviewNotableFeesChangesFamiliesPatent listSources & methods

Five patents currently held, every record listed here

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Sep 2042. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Sep 2042
Next term end
5
Patent families

When these terms end

Each bar runs from grant to computed term end. 2025 to 2045.
US 12,465,647 1'-Alkyl Modified Ribose Derivatives and Methods of Use Sep 19, 2042
US 12,747,257 Polyhydroxylated Cyclopentane Derivatives and Methods of Use Jan 13, 2043
US 12,703,865 Small Interfering RNA Targeting C3 and Uses Thereof Oct 16, 2043
US 12,636,301 5'-Modified Carbocyclic Ribonucleotide Derivatives and Methods of Use Aug 23, 2044
US 12,735,709 Small Interfering RNA Targeting CFB and Uses Thereof Jun 17, 2045
20292033203720412045
12 pending applications: term is not computable until grant.Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 1 of the currently held patents qualifies as notable.

Fee deadlines

No maintenance fee falls due on this company's record before Nov 17, 2027.

Recent changes

  • 2 of the patents on this record were granted since Aug 21, 2026

What they patent

The 3 largest of its 5 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.

Patents held now

Soonest term end first.

Showing 1 to 5 of 5

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatusExpiresConfidence
US 12,465,6471'-Alkyl Modified Ribose Derivatives and Methods of Use
In force
 · High confidence
In forceHigh confidence
US 12,747,257Polyhydroxylated Cyclopentane Derivatives and Methods of Use
In force
 · High confidence
In forceHigh confidence
US 12,703,865Small Interfering RNA Targeting C3 and Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 12,636,3015'-Modified Carbocyclic Ribonucleotide Derivatives and Methods of Use
In force
 · High confidence
In forceHigh confidence
US 12,735,709Small Interfering RNA Targeting CFB and Uses Thereof
In force
 · Medium confidence
In forceMedium confidence
Also on record, not counted in the 5: 12 applications pending · 6 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
1 computed term date comes from a chain with an unresolved parent. A continuity parent has not yet been fetched from USPTO's records. The term is dated from this application's own claim; no earlier date is assumed until the parent is resolved.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited